Form 4: Annexon CFO Granted Significant Equity Awards

Annexon, Inc.'s EVP & CFO, Jennifer Lew, was granted 62,500 restricted stock units and options to purchase 250,000 shares of common stock.

Summary

• Jennifer Lew, Executive Vice President and Chief Financial Officer of Annexon, Inc., was granted equity awards.
• The awards include 62,500 restricted stock units (RSUs) for which she is entitled to receive one share of Common Stock per RSU upon vesting.
• The RSUs will vest in three annual installments, with the first 1/3rd vesting on February 19, 2027, subject to continuous service.
• Additionally, Ms. Lew was granted stock options to purchase 250,000 shares of Common Stock with an exercise price of $5.1 per share.
• These stock options will vest monthly over four years, with 1/48th vesting on each monthly anniversary from February 19, 2026, becoming fully vested on February 19, 2030.
• The option grant has an expiration date of February 19, 2036.
• Following these transactions, Ms. Lew beneficially owns 176,265 shares of Common Stock and 250,000 derivative securities (stock options).
• The transaction was made pursuant to a Rule 10b5-1(c) plan, which allows for pre-arranged trading plans.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices that align management's interests with long-term shareholder value, without indicating any immediate operational or financial changes.

Positives

• The grant of restricted stock units and stock options aligns the Chief Financial Officer's long-term interests with those of the shareholders, incentivizing performance and retention.
• Equity compensation is a standard practice for executive remuneration, reflecting confidence in the company's future prospects.

Future Outlook

The vesting schedules for the RSUs and stock options extend several years into the future, indicating an expectation of continued service from the CFO and a long-term incentive structure tied to the company's performance.

Industry Context

StockSavvy.ai notes that equity compensation, such as restricted stock units and stock options, is a prevalent and standard practice within the biotechnology and pharmaceutical industries. It serves as a key mechanism to attract, retain, and motivate executive talent by aligning their financial success with the long-term growth and shareholder value of the company.

Comparison to Industry Standards

• The use of RSUs and stock options for executive compensation is a common practice across the biotech sector, similar to companies like Biogen Inc. or Amgen Inc., which frequently utilize such instruments to incentivize their leadership.
• The vesting schedules (annual for RSUs, monthly over four years for options) are typical for executive equity grants, designed to ensure long-term commitment and performance.

Stakeholder Impact

• Shareholders: The equity grants are designed to align the CFO's financial interests with shareholder value creation, potentially leading to more focused long-term decision-making.
• Employees: Standard executive compensation practices can set a precedent for broader employee incentive programs, though these specific grants are for a senior executive.

Next Steps

• Vesting of 1/3rd of RSUs on February 19, 2027, and annually thereafter.
• Monthly vesting of stock options commencing February 19, 2026, until fully vested on February 19, 2030.

Key Dates

Keywords

Annexon, ANNX, Jennifer Lew, CFO, Restricted Stock Units, RSUs, Stock Options, Equity Compensation, Insider Transaction, Executive Compensation, Form 4, 10b5-1 plan